Check-in, have coffee, and get to know other guests before the event starts.

Kelli Grand, Implementation Manager, Benchling

Meritxell Orpinell, Leader - Professional Services, Benchling

Willi Gottstein, Scientist, DSM

DSM is a global purpose-led, science-based company specialising in Nutrition, Health & Sustainable Living. Our purpose is to create brighter lives for all. We achieve it by using all the scientific and innovation power at our disposal to tackle some of the world’s greatest challenges. In this presentation we will briefly illustrate how innovation can be accelerated and improved through the combination of lab automation and AI.

Tobias Wingbermühle, Chief Commercial Officer, Clustermarket

Laboratories are one sector that can benefit most from standardization, especially when it comes to performance. Without strict guidelines or standards to abide by, labs are often forced to rely on themselves to figure out how to produce not just a high volume of relevant results but reproducible ones too. The difficulty with standardising KPIs stems from the nature of scientific research, as performance criteria are nearly always different from lab to lab. With that in mind, there are still a few key performance indicators (KPIs) relevant to the scientific continuum, complete with optimised methods of analysing and reporting them to help assess your lab’s level of efficiency.

Andrew Smith | Leader, Business Development, Benchling

In vivo studies are an essential component of biopharmaceutical R&D that help teams understand drug pharmacology, safety, and toxicology. They sit on the critical path to bringing new drugs into the clinic, so it’s imperative to run them accurately, efficiently, and collaboratively. Yet many teams still struggle to manage the end-to-end process of running in vivo studies using spreadsheets, email, and outdated point solutions. Modern drug development teams require an in vivo solution that aligns with the specialised nature of vivarium work, yet also remains connected to their broader R&D programs. In this session, we will share some of the frequent challenges observed across the industry, followed by real-world examples of companies modernising their in vivo programs. We'll provide insights on how to drive collaboration across R&D teams and accelerate time to clinic by leveraging connected, cloud-based R&D applications that facilitate sample transfers for bioanalysis and joining of data for scientific decision-making.

Moderator: Kelli Grand, Implementation Consultant, Benchling

Biotherapeutics, including biologics, RNA-based therapeutics, cell and gene therapies, and vaccines, have positively transformed global public health. Join your peers and Benchling experts to discuss strategies for effective data management, traceability of results, and optimisation of workflows that are accelerating the advancement of these promising new modalities.

Moderator: Veronique De Vroey, Senior Director Screening & Research Operations, Galapagos

Today’s advanced biomolecules require new ways of conducting R&D. To get breakthrough molecules to milestone faster, organisations need modern software that connects work across R&D so groups can operate as a unified team. We will discuss challenges with traditional LIMS and explore how cloud software helps teams advance novel biomolecules into marketable products.

Connect, and unwind with quality conversations and delicious food.